Mian-Ling Zhong

Mian-Ling Zhong

Auto-generated profile, based on publicly available information

Mian-Ling Zhong

Children's Medical Center of the Affiliated Hospital of Guangdong Medical University, Zhanjiang, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2019 in Jornal de Pediatria
Verified
Journal Article
Open access
MZMianling Zhong
Mianling Zhong
YHYuge Huang
Yuge Huang
TLTufeng Li
Tufeng Li
LXLu Xiong
Lu Xiong
TLTing Lin
Ting Lin
DHDongqiang He
Dongqiang He
This study aimed to evaluate the predictive validity of the day-1 PELOD-2 and day-1 "quick" PELOD-2 (qPELOD-2) scores for in-hospital mortality in children with sepsis in a pediatric intensive care unit (PICU) of a developing country. The data of 516 children diagnosed as sepsis were retrospectively analyzed. The children were divided into survival group and non-survival group, according to the clinical outcome 28 days after admission. Day-1 PELOD-2, day-1 qPELOD-2, pediatric SOFA (pSOFA), and P-MODS were collected and scored. Receiver operating characteristic (ROC) curves were plotted, and the efficiency of the day-1 PELOD-2, day-1 qPELOD-2 score, pSOFA, and P-MODS for predicting death were evaluated by the area under the ROC curve (AUC). The day-1 PELOD-2 score, day-1 qPELOD-2 score, pSOFA, and P-MODS in the non-survivor group were significantly higher than those in the survivor group. ROC curve analysis showed that the AUCs of the day-1 PELOD-2 score, day-1 qPELOD-2 score, pSOFA, and P-MODS for predicting the prognosis of children with sepsis in the PICU were 0.916, 0.802, 0.937, and 0.761, respectively (all p < 0.05). Both the day-1 PELOD-2 score and day-1 qPELOD-2 score were effective and able to assess the prognosis of children with sepsis in a PICU of a developing country. Additionally, the day-1 PELOD-2 score was superior to the day-1 qPELOD-2 score. Further studies are needed to verify the usefulness of the day-1 qPELOD-2 score, particularly outside of the PICU.

24 June 2020 in Current Gene Therapy
Verified
Journal Article
Closed access
PDF file
ZMZhong Mian-Ling
Zhong Mian-Ling
CYChao Yun-Qi
Chao Yun-Qi
CZChaochun Zou
Chaochun Zou
Prader-Willi syndrome (PWS) is an imprinted neurodevelopmental disease characterized by cognitive impairments, developmental delay, hyperphagia, obesity, and sleep abnormalities. It is caused by a lack of expression of the paternally active genes in the PWS imprinting center on chromosome 15 (15q11.2-q13). Owing to the imprinted gene regulation, the same genes in the maternal chromosome, 15q11-q13, are intact in structure but repressed at the transcriptional level because of the epigenetic mechanism. The specific molecular defect underlying PWS provides an opportunity to explore epigenetic therapy to reactivate the expression of repressed PWS genes inherited from the maternal chromosome. The purpose of this review is to summarize the main advances in the molecular study of PWS and discuss current and future perspectives on the development of CRISPR/Cas9- mediated epigenome editing in the epigenetic therapy of PWS. Twelve studies on the molecular mechanism or epigenetic therapy of PWS were included in the review. Although our understanding of the molecular basis of PWS has changed fundamentally, there has been a little progress in the epigenetic therapy of PWS that targets its underlying genetic defects.


26 February 2021 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
PDF file
MZMian-Ling Zhong
Mian-Ling Zhong
YSYe-Mei Song
Ye-Mei Song
CZChaochun Zou
Chaochun Zou
Deletions of the long arm of chromosome 6 are rare and are characterized by great clinical variability according to the deletion breakpoint. Herein, we reported a 3-year-old girl evaluated for facial dysmorphism (long and connected eyebrows, big mouth, wide nasal bridge, high palatine arch, low set ears, and thin hair), growth retardation, intellectual disability, and language delay. Chromosomal microarray analysis revealed an 8.1-Mb deletion within 6q25.1-q25.3 ([hg19] chr6: 152,307,705-160,422,834) comprising 31 genes. Dysmorphic features, microcephaly, intellectual disability, language delay, growth retardation, and corpus callosum dysgenesis were commonly reported. Hence, 6q25 microdeletion is a rare condition. In patients with dysmorphic features, microcephaly, growth retardation, intellectual disability, language delay and corpus callosum dysgenesis, 6q25 microdeletion should be considered in the differential diagnosis and chromosomal microarray analysis should be performed to confirm the diagnosis.

1 September 2020 in Jornal de Pediatria (Versão em Português)
Verified
Journal Article
Open access
MZMianling Zhong
Mianling Zhong
YHYuge Huang
Yuge Huang
TLTufeng Li
Tufeng Li
LXLu Xiong
Lu Xiong
TLTing Lin
Ting Lin
DHDongqiang He
Dongqiang He
This study aimed to evaluate the predictive validity of the day‐1 PELOD‐2 and day‐1 “quick” PELOD‐2 (qPELOD‐2) scores for in‐hospital mortality in children with sepsis in a pediatric intensive care unit (PICU) of a developing country. The data of 516 children diagnosed as sepsis were retrospectively analyzed. The children were divided into survival group and non‐survival group, according to the clinical outcome 28 days after admission. Day‐1 PELOD‐2, day‐1 qPELOD‐2, pediatric SOFA (pSOFA), and P‐MODS were collected and scored. Receiver operating characteristic (ROC) curves were plotted, and the efficiency of the day‐1 PELOD‐2, day‐1 qPELOD‐2 score, pSOFA, and P‐MODS for predicting death were evaluated by the area under the ROC curve (AUC). The day‐1 PELOD‐2 score, day‐1 qPELOD‐2 score, pSOFA, and P‐MODS in the non‐survivor group were significantly higher than those in the survivor group. ROC curve analysis showed that the AUCs of the day‐1 PELOD‐2 score, day‐1 qPELOD‐2 score, pSOFA, and P‐MODS for predicting the prognosis of children with sepsis in the PICU were 0.916, 0.802, 0.937, and 0.761, respectively (all p < 0.05). Both the day‐1 PELOD‐2 score and day‐1 qPELOD‐2 score were effective and able to assess the prognosis of children with sepsis in a PICU of a developing country. Additionally, the day‐1 PELOD‐2 score was superior to the day‐1 qPELOD‐2 score. Further studies are needed to verify the usefulness of the day‐1 qPELOD‐2 score, particularly outside of the PICU. A finalidade de nosso estudo foi avaliar a validade preditiva dos escores PELOD‐2 no dia 1 e “quick” PELOD‐2 no dia 1 com relação à mortalidade hospitalar em crianças com sepse em uma UTIP de um país em desenvolvimento. Foram analisados retrospectivamente os dados de 516 crianças diagnosticadas com sepse. As crianças foram divididas em grupo sobrevida e grupo não sobrevida de acordo com o desfecho clínico de 28 dias após internação. Foram coletadas e pontuadas as variáveis PELOD‐2 no dia 1, qPELOD‐2 no dia 1, pediatric Sequential Organ Failure Assessment (pSOFA) e Pediatric Multiple Organ Dysfunction Score (P‐MODS). A curva da característica de operação do receptor (ROC) foi plotada e a eficiência preditiva do PELOD‐2 no dia 1, o escore qPELOD‐2 no dia 1, pSOFA, P‐MODS com relação a óbito foram avaliados pela área abaixo da curva (AUC) da curva ROC. O escore PELOD‐2 no dia 1, escore qPELOD‐2 no dia 1, pSOFA e P‐MODS no grupo não sobrevida foram significativamente maiores do que os no grupo sobrevida. A análise preditiva da curva ROC mostrou que as AUCs do escore PELOD‐2 no dia 1, escore qPELOD‐2 no dia 1, pSOFA e P‐MODS com relação ao prognóstico de crianças com sepse na UTIP foi 0,916, 0,802, 0,937 e 0,761, respectivamente (todas p < 0,05). Tanto o escore PELOD‐2 no dia 1 e o escore qPELOD‐2 no dia 1 foram válidos e conseguiram avaliar o prognóstico de crianças com sepse em uma UTIP de um país em desenvolvimento. Além disso, o escore PELOD‐2 no dia 1 foi superior ao escore qPELOD‐2 no dia 1. São necessários estudos adicionais para verificar a utilidade do escore qPELOD‐2 no dia 1, principalmente fora da UTIP.